Breaking news · Updated 10-29-2026

BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax: Compounding Status for Telehealth Brands

By the GrowPro team, led by Jessica Lynne White, PT · Published 10-29-2026 · growpro.co

Short answer: As of the 10-28-2026 HHS notice, BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax fall under temporary enforcement discretion: licensed compounding pharmacies can make them while the FDA completes rulemaking. None is FDA approved. A telehealth brand can offer them only with provider evaluation, a valid prescription and a licensed pharmacy.

The short version

On Wednesday, October 28, 2026, the U.S. Department of Health and Human Services announced temporary enforcement discretion for six peptides: BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. In plain terms, the FDA will not take action against licensed compounding pharmacies that make these six while it completes formal rulemaking on whether to add them to the list of bulk drug substances pharmacies may use. Pharmacies that compound them are expected to certify the identity and purity of what they make and to report side effects. The notice was reported as scheduled for publication in the Federal Register on Friday, October 30, 2026.

How the six got here

Compounding pharmacies can generally use a bulk ingredient only if it meets federal criteria, such as appearing on the FDA's 503A bulks list. In July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides and voted to recommend six of them for that list. Advisory votes are not final. The October 28 enforcement discretion bridges the gap: the FDA will not act against licensed pharmacies compounding these six while the formal rule is written.

Status, peptide by peptide

For each of the six, the regulatory status is the same: covered by HHS's temporary enforcement discretion as of 10-28-2026, not FDA approved, available only by prescription through a licensed compounding pharmacy that certifies identity and purity. BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax should each appear on your site with accurate, claim-free descriptions. We deliberately do not describe what any of them does: those statements are exactly what regulators and ad platforms scrutinize.

What is not covered

Peptides outside these six are not covered by this notice. DSIP, reviewed at the same July meeting, was not recommended. Other peptides have their own status under federal compounding rules, so never assume a peptide is available because it is popular. Confirm each one with your pharmacy partner and healthcare counsel before it appears anywhere.

What a telehealth brand needs before offering any of the six

A licensed provider network in the states you serve, with written protocols for each peptide. A licensed 503A pharmacy partner ready to compound them, with certificates of analysis on file and a process for side-effect reporting. An intake that screens appropriately and routes every patient to a provider. Accurate product pages and consent language. LegitScript certification and payment processing that allow the category. And a catalog that does not depend on these six alone.

How GrowPro handles it

GrowPro builds the whole system with you: brand, compliant website, WellieMD platform, provider and pharmacy activation, LegitScript and payments. All six peptides can sit in your formulary from launch, and existing GrowPro founders can add them to the brand they already run.

Already a GrowPro founder? All six peptides can be added to the brand you run today. Talk to our team.

Frequently asked questions

Is BPC-157 available through telehealth now?

Through a compliant model, yes, for now: a licensed provider can prescribe it and a licensed compounding pharmacy can prepare it under HHS's temporary enforcement discretion announced 10-28-2026. It is not FDA approved and the policy can change.

Is TB-500 the same status as BPC-157?

Yes. Both are among the six peptides covered by the 10-28-2026 enforcement discretion, along with Epitalon, KPV, MOTS-c and Semax.

Was DSIP included?

No. DSIP was reviewed at the July 2026 FDA advisory meeting but was not recommended, and it is not one of the six covered peptides.

Can I describe what these peptides do on my website?

Avoid it. Benefit, healing or treatment claims for compounded, unapproved substances are a core enforcement and ad-policy risk. Describe the program, the process and the safeguards instead.

Sources

This article is general education, not legal or medical advice. The six peptides named here are not FDA-approved drugs, and the HHS enforcement discretion is temporary and may change. Confirm current status with your pharmacy partner and healthcare counsel.